Condition (MeSH)
Pyoderma Gangrenosum
ClinicalTrials.gov lists 36 trials for Pyoderma Gangrenosum or a narrower condition beneath it. XOMA (US) LLC has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
36 of the 36 trials are tagged with Pyoderma Gangrenosum itself; the rest are tagged with a narrower condition beneath it.
When did Pyoderma Gangrenosum trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 2 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 4 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 1 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Pyoderma Gangrenosum trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 17 |
| Phase 3 | 7 |
| Phase 4 | 2 |
| Not applicable | 2 |
| Observational | 5 |
How many Pyoderma Gangrenosum trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 4 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Completed | 12 |
| Terminated | 8 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Pyoderma Gangrenosum trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| XOMA (US) LLC | 4 |
| AbbVie | 2 |
| InflaRx GmbH | 2 |
| Arena Pharmaceuticals | 1 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Pyoderma Gangrenosum? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Gevokizumab | 4 |
| Spesolimab | 2 |
| IFX-1 | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Adalimumab-US | 3 |
| gevokizumab open-label | 2 |
| SHR-1139 Injection | 2 |
| Secukinmab | 2 |
| Hyperbaric Oxygen | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Pyoderma Gangrenosum trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| sepsis | 2 | 1 |
| Endocarditis | 1 | 1 |
| Erysipelas | 1 | 1 |
| Intervertebral discitis | 1 | 1 |
| Pneumonia | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Pyoderma Gangrenosum? (20)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Successful treatment of a refractory pyoderma gangrenosum with risankizumab. | International wound journal | 2020 | Yes |
| Pyoderma gangrenosum. | Nature reviews. Disease primers | 2020 | Yes |
| Tofacitinib for the Treatment of Pyoderma Gangrenosum. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2019 | Yes |
| Dysregulation of inflammatory gene expression in lesional and nonlesional skin of patients with pyoderma gangrenosum. | The British journal of dermatology | 2018 | Yes |
| Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. | The British journal of dermatology | 2018 | Yes |
Showing 5 of 20 publications.
Prevalence (18)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Pyoderma gangrenosum | Annual incidence | 1-9 / 1 000 000 | United Kingdom | GB | Unspecified |
| Pyoderma gangrenosum | Annual incidence | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Pyoderma gangrenosum | Annual incidence | 1-9 / 1 000 000 | United Kingdom | GB | Exact |
| Pyoderma gangrenosum | Annual incidence | 1-9 / 100 000 | United States | US | Unspecified |
| Pyoderma gangrenosum | Annual incidence | 1-9 / 100 000 | United States | US | Exact |
Showing 5 of 18 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Pyoderma gangrenosum | 48104 | Exact | Orphadata Science knowledge files, Product 1 |
| Pyoderma gangrenosum | 48104 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.